NASDAQ:FIXX - Homology Medicines Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$25.76 -2.59 (-9.14 %)
(As of 03/24/2019 01:00 AM ET)
Previous Close$25.76
Today's Range$25.70 - $28.24
52-Week Range$15.07 - $31.80
Volume106,519 shs
Average Volume181,197 shs
Market Capitalization$967.03 million
P/E Ratio-12.88
Dividend YieldN/A
BetaN/A
Homology Medicines, Inc., a genetic medicines company, focuses on translating proprietary gene editing and gene therapy technologies into novel treatments for patients with rare diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing modality across a range of genetic disorders. The company's various set of AAVHSCs allows company to target, via a single intravenous injection, a range of disease-relevant tissues, including the liver, central nervous system, bone marrow, lung, muscle and eye, across modalities—gene editing and gene therapy. Homology Medicines, Inc. was founded in 2015 and is based in Bedford, Massachusetts.

Receive FIXX News and Ratings via Email

Sign-up to receive the latest news and ratings for FIXX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:FIXX
CUSIPN/A
Phone781-301-7277

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$3.68 million
Book Value$5.19 per share

Profitability

Net Income$-57,220,000.00
Net Margins-1,553.07%

Miscellaneous

EmployeesN/A
Market Cap$967.03 million
Next Earnings Date5/13/2019 (Estimated)
OptionableNot Optionable

Homology Medicines (NASDAQ:FIXX) Frequently Asked Questions

What is Homology Medicines' stock symbol?

Homology Medicines trades on the NASDAQ under the ticker symbol "FIXX."

How were Homology Medicines' earnings last quarter?

Homology Medicines Inc (NASDAQ:FIXX) posted its quarterly earnings results on Tuesday, March, 12th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.44) by $0.07. The business earned $0.98 million during the quarter. Homology Medicines had a negative return on equity of 39.14% and a negative net margin of 1,553.07%. View Homology Medicines' Earnings History.

When is Homology Medicines' next earnings date?

Homology Medicines is scheduled to release their next quarterly earnings announcement on Monday, May 13th 2019. View Earnings Estimates for Homology Medicines.

What price target have analysts set for FIXX?

7 brokerages have issued 12-month price objectives for Homology Medicines' shares. Their predictions range from $18.50 to $37.00. On average, they expect Homology Medicines' stock price to reach $30.5833 in the next year. This suggests a possible upside of 18.7% from the stock's current price. View Analyst Price Targets for Homology Medicines.

What is the consensus analysts' recommendation for Homology Medicines?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Homology Medicines in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Homology Medicines.

Has Homology Medicines been receiving favorable news coverage?

News coverage about FIXX stock has been trending somewhat negative this week, InfoTrie Sentiment reports. InfoTrie identifies negative and positive press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Homology Medicines earned a media sentiment score of -1.4 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near future.

Who are some of Homology Medicines' key competitors?

What other stocks do shareholders of Homology Medicines own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Homology Medicines investors own include Micron Technology (MU), NVIDIA (NVDA), Global Blood Therapeutics (GBT), Snap (SNAP), Alibaba Group (BABA), BioTelemetry (BEAT), Intel (INTC), AT&T (T), Neurocrine Biosciences (NBIX) and Portola Pharmaceuticals (PTLA).

Who are Homology Medicines' key executives?

Homology Medicines' management team includes the folowing people:
  • Dr. Arthur O. Tzianabos, Pres, CEO & Director (Age 56)
  • Mr. W. Bradford Smith, CFO, Treasurer & Sec. (Age 63)
  • Mr. Albert Seymour Ph.D., Chief Scientific Officer (Age 51)
  • Dr. Saswati Chatterjee, Co-Founder & Chair of Scientific Advisory Board
  • Dr. Siyamak Rasty Ph.D., Chief Operating Officer (Age 55)

When did Homology Medicines IPO?

(FIXX) raised $100 million in an initial public offering (IPO) on Wednesday, March 28th 2018. The company issued 6,700,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Evercore ISI acted as the underwriters for the IPO and BTIG was co-manager.

Who are Homology Medicines' major shareholders?

Homology Medicines' stock is owned by many different of retail and institutional investors. Top institutional investors include FMR LLC (5.63%), RTW Investments LP (4.36%), BlackRock Inc. (3.89%), VV Manager LLC (2.06%), Lord Abbett & CO. LLC (0.74%) and Northern Trust Corp (0.48%). Company insiders that own Homology Medicines stock include James E Flynn, Kush Parmar, Ventures Iv LP 5Am and Vida Ventures, Llc. View Institutional Ownership Trends for Homology Medicines.

Which institutional investors are selling Homology Medicines stock?

FIXX stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Lord Abbett & CO. LLC, Sphera Funds Management LTD. and Victory Capital Management Inc.. Company insiders that have sold Homology Medicines company stock in the last year include Kush Parmar and Ventures Iv LP 5Am. View Insider Buying and Selling for Homology Medicines.

Which institutional investors are buying Homology Medicines stock?

FIXX stock was acquired by a variety of institutional investors in the last quarter, including RTW Investments LP, BlackRock Inc., VV Manager LLC, Polar Capital LLP, Northern Trust Corp, Geode Capital Management LLC, Geode Capital Management LLC and Bank of New York Mellon Corp. Company insiders that have bought Homology Medicines stock in the last two years include James E Flynn and Vida Ventures, Llc. View Insider Buying and Selling for Homology Medicines.

How do I buy shares of Homology Medicines?

Shares of FIXX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Homology Medicines' stock price today?

One share of FIXX stock can currently be purchased for approximately $25.76.

How big of a company is Homology Medicines?

Homology Medicines has a market capitalization of $967.03 million and generates $3.68 million in revenue each year. The company earns $-57,220,000.00 in net income (profit) each year or ($2.00) on an earnings per share basis.

What is Homology Medicines' official website?

The official website for Homology Medicines is http://www.homologymedicines.com.

How can I contact Homology Medicines?

Homology Medicines' mailing address is One Patriots Park, BEDFORD MA, 01730. The company can be reached via phone at 781-301-7277.


MarketBeat Community Rating for Homology Medicines (NASDAQ FIXX)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  48 (Vote Outperform)
Underperform Votes:  41 (Vote Underperform)
Total Votes:  89
MarketBeat's community ratings are surveys of what our community members think about Homology Medicines and other stocks. Vote "Outperform" if you believe FIXX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FIXX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/24/2019 by MarketBeat.com Staff

Featured Article: Quick Ratio

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel